ABSTRACT
Dyslipidemia plays critical roles in the pathogenesis of coronary atherosclerosis, a chronic inflammatory disease. Vascular inflammation also triggers the onset of acute complications of atherosclerosis, such as myocardial infarction. Advances in cardiovascular medicine demonstrate that lipid-lowering therapy by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) likely prevents acute coronary complications by limiting vascular inflammation. In particular, recent clinical evidence indicates aggressive lipid-lowering treatment for patients at risk. Preclinical studies also support the concept of anti-inflammatory properties of lipid lowering by either diet or statins. Therefore, dyslipidemia is the primary target of therapy for the prevention of coronary atherosclerosis and its acute thrombotic complications. Nevertheless, even aggressive statin therapy does not forestall many adverse events. Thus, current cardiovascular medicine also seeks mechanisms to mitigate vascular inflammation and atherosclerosis other than addressing low-density lipoprotein, and new therapeutic strategies beyond lipid lowering.
KEYWORDS
Atherosclerosis - inflammation - macrophages - HMG-CoA reductase inhibitors - plaque stabilization
REFERENCES
1
Grundy S M, Cleeman J I, Merz C N et al..
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Circulation.
2004;
110
227-239
2
Aikawa M, Libby P.
The vulnerable atherosclerotic plaque; pathogenesis and therapeutic approach.
Cardiovasc Pathol.
2004;
13
125-138
3
Anitschkow N, Chalatow S.
On experimental cholesterin steatosis and its significance in the origin of some pathological processes (1913).
Arteriosclerosis.
1983;
3
178-182
4
Vesselinovitch D.
Animal models and the study of atherosclerosis.
Arch Pathol Lab Med.
1988;
112
1011-1017
5 Aikawa M, Fukumoto Y, Rabkin E, Libby P. Rabbit models of atherosclerosis. In: Daniel I. Simon, Rogers C Vascular Disease and Injury: Preclinical Research Totowa, NJ; Humana Press 2000: 175-191
6
LaRosa J C, Hunninghake D, Bush D et al..
The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association.
Circulation.
1990;
81
1721-1733
7
Libby P, Aikawa M, Schonbeck U.
Cholesterol and atherosclerosis.
Biochim Biophys Acta.
2000;
1529
299-309
8
Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L.
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
N Engl J Med.
1989;
320
915-924
9 Tshimikas S, Glass C K, Steinberg D, Witztum J L. Lipoprotein oxidation, macrophages, immunity, and atherogenesis. In: Chein KR Molecular Basis of Cardiovascular Disease Philadelphia; Saunders 2004: 385-413
10
Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M.
Type I macrophage scavenger receptor contains alphaα-helical and collagen-like coiled coils.
Nature.
1990;
343
531-535
11 Gotto A M, Farmer J A. Lipid-lowering trials. In: Braunwald E, Zipes DP, Libby P Heart Disease: A Text Book of Cardiovascular Medicine Philadelphia; WB Saunders 2001: 126-146
12
Libby P, Aikawa M.
Stabilization of atherosclerotic plaques: new mechanisms and clinical targets.
Nat Med.
2002;
8
1257-1262
13
Kinlay S, Timms T, Clark M et al..
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.
Am J Cardiol.
2002;
89
1205-1207
14
van Wissen S, Trip M D, Smilde T J, de Graaf J, Stalenhoef A F, Kastelein J J.
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Atherosclerosis.
2002;
165
361-366
15
Taylor A J, Kent S M, Flaherty P J, Coyle L C, Markwood T T, Vernalis M N.
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Circulation.
2002;
106
2055-2060
16
Cannon C P, Braunwald E, McCabe C H et al..
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
N Engl J Med.
2004;
350
1495-1504
17
Nissen S E, Tuzcu E M, Schoenhagen P et al..
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
JAMA.
2004;
291
1071-1080
18
Fuster V, Badimon L, Badimon J J, Chesebro J H.
The pathogenesis of coronary artery disease and the acute coronary syndromes.
N Engl J Med.
1992;
326
242-250
310-318
19
Libby P.
Molecular bases of the acute coronary syndromes.
Circulation.
1995;
91
2844-2850
20
Moreno P R, Falk E, Palacios I F, Newell J B, Fuster V, Fallon J T.
Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture.
Circulation.
1994;
90
775-778
21
van der Wal A C, Becker A E, van der Loos C M, Das P K.
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.
Circulation.
1994;
89
36-44
22
Galis Z S, Sukhova G K, Lark M W, Libby P.
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
J Clin Invest.
1994;
94
2493-2503
23
Sukhova G, Schoenbeck U, Rabkin E et al..
Evidence of increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques.
Circulation.
1999;
99
2503-2509
24
Herman M P, Sukhova G K, Libby P et al..
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling.
Circulation.
2001;
104
1899-1904
25
Brinckerhoff C E, Matrisian L M.
Matrix metalloproteinases: a tail of a frog that became a prince.
Nat Rev Mol Cell Biol.
2002;
3
207-214
26
Fukumoto Y, Deguchi J, Libby P et al..
Genetically-determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques.
Circulation.
2004;
, In press
27
Libby P, Mach F, Schoenbeck U, Bourcier T, Aikawa M.
Regulation of the thrombotic potential of atheroma.
Thromb Haemost.
1999;
82
736-741
28
Farb A, Burke A P, Tang A L et al..
Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death.
Circulation.
1996;
93
1354-1363
29
Bombeli T, Karsan A, Tait J F, Harlan J M.
Apoptotic vascular endothelial cells become procoagulant.
Blood.
1997;
89
2429-2442
30
Rajavashisth T B, Liao J K, Galis Z S et al..
Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase.
J Biol Chem.
1999;
274
11924-11929
31
Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P.
Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression. Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis.
Arterioscler Thromb Vasc Biol.
2004;
24
1309-1314
32
Lindstedt K A, Leskinen M J, Kovanen P T.
Proteolysis of the pericellular matrix: a novel element determining cell survival and death in the pathogenesis of plaque erosion and rupture.
Arterioscler Thromb Vasc Biol.
2004;
24
1350-1358
33
Griendling K K, FitzGerald G A.
Oxidative stress and cardiovascular injury.
Circulation.
2003;
108
1912-1916
2034-2040
34
Kume N, Cybulsky M I, Gimbrone Jr M A.
Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells.
J Clin Invest.
1992;
90
1138-1144
35
Khan B V, Parthasarathy S S, Alexander R W, Medford R M.
Modified low density lipoprotein and its constituents augment cytokine- activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells.
J Clin Invest.
1995;
95
1262-1270
36
Cushing S D, Berliner J A, Valente A J et al..
Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.
Proc Natl Acad Sci U S A.
1990;
87
5134-5138
37
Collins T, Cybulsky M I.
NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?.
J Clin Invest.
2001;
107
255-264
38
Sakai M, Kobori S, Miyazaki A, Horiuchi S.
Macrophage proliferation in atherosclerosis.
Curr Opin Lipidol.
2000;
11
503-509
39
Tsao P S, McEvoy L M, Drexler H, Butcher E C, Cooke J P.
Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine.
Circulation.
1994;
89
2176-2182
40
De Caterina R, Libby P, Peng H B et al..
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.
J Clin Invest.
1995;
96
60-68
41
Khan B V, Harrison D G, Olbrych M T, Alexander R W, Medford R M.
Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells.
Proc Natl Acad Sci U S A.
1996;
93
9114-9119
42
Tsao P S, Wang B, Buitrago R, Shyy J Y, Cooke J P.
Nitric oxide regulates monocyte chemotactic protein-1.
Circulation.
1997;
96
934-940
43
Oemar B S, Tschudi M R, Godoy N, Brovkovich V, Malinski T, Luscher T F.
Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis.
Circulation.
1998;
97
2494-2498
44
Aikawa M, Sugiyama S, Hill C et al..
Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma.
Circulation.
2002;
106
1390-1396
45
Liao J K, Shin W S, Lee W Y, Clark S L.
Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase.
J Biol Chem.
1995;
270
319-324
46
Davignon J, Ganz P.
Role of endothelial dysfunction in atherosclerosis.
Circulation.
2004;
109
III27-III32
47
Suwaidi J A, Hamasaki S, Higano S T, Nishimura R A, Holmes Jr D R, Lerman A.
Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.
Circulation.
2000;
101
948-954
48
Halcox J PJ, Schenke W H, Zalos G et al..
Prognostic value of coronary vascular endothelial dysfunction.
Circulation.
2002;
106
653-658
49
Yla-Herttuala S, Palinski W, Rosenfeld M E et al..
Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man.
J Clin Invest.
1989;
84
1086-1095
50
Ehara S, Ueda M, Naruko T et al..
Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.
Circulation.
2001;
103
1955-1960
51
Miller Y I, Chang M K, Binder C J, Shaw P X, Witztum J L.
Oxidized low density lipoprotein and innate immune receptors.
Curr Opin Lipidol.
2003;
14
437-445
52
Tsimikas S, Bergmark C, Beyer R W et al..
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
J Am Coll Cardiol.
2003;
41
360-370
53
Heinecke J W.
Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis.
Am J Cardiol.
2003;
91
12A-16A
54
Sugiyama S, Okada Y, Sukhova G K, Virmani R, Heinecke J W, Libby P.
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.
Am J Pathol.
2001;
158
879-891
55
Baldus S, Heeschen C, Meinertz T et al..
Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes.
Circulation.
2003;
108
1440-1445
56
Aikawa M, Rabkin E, Okada Y et al..
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization.
Circulation.
1998;
97
2433-2444
57
Aikawa M, Rabkin E, Voglic S J et al..
Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma.
Circ Res.
1998;
83
1015-1026
58
Aikawa M, Voglic S J, Sugiyama S et al..
Dietary lipid lowering reduces tissue factor expression in rabbit atheroma.
Circulation.
1999;
100
1215-1222
59
Williams J K, Sukhova G K, Herrington D M, Libby P.
Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys.
J Am Coll Cardiol.
1998;
31
684-691
60
Aikawa M, Rabkin E, Sugiyama S et al..
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vivo.
Circulation.
2001;
103
276-283
61
Fukumoto Y, Libby P, Rabkin E et al..
Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits.
Circulation.
2001;
103
993-999
62
Liao J K.
Isoprenoids as mediators of the biological effects of statins.
J Clin Invest.
2002;
110
285-288
63
Davignon J.
Beneficial cardiovascular pleiotropic effects of statins.
Circulation.
2004;
109
III39-III43
64
Crisby M, Nordin-Fredriksson G, Shah P K, Yano J, Zhu J, Nilsson J.
Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization.
Circulation.
2001;
103
926-933
65
Blake G J, Ridker P M.
C-reactive protein and other inflammatory risk markers in acute coronary syndromes.
J Am Coll Cardiol.
2003;
41
37S-42S
65a
Ridker P M, Cannon C P, Morrow D et al..
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy.
N Engl J Med.
2005;
352
20-28
66
Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E.
Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis.
Arterioscler Thromb Vasc Biol.
1997;
17
265-272
67
Laufs U, La Fata V, Plutzky J, Liao J K.
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Circulation.
1998;
97
1129-1135
68
Guijarro C, Blanco-Colio L M, Ortego M et al..
3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.
Circ Res.
1998;
83
490-500
69
Kwak B, Mulhaupt F, Myit S, Mach F.
Statins as a newly recognized type of immunomodulator.
Nat Med.
2000;
6
1399-1402
70
Mulhaupt F, Matter C M, Kwak B R et al..
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Cardiovasc Res.
2003;
59
755-766
71
Mach F.
Statins as novel immunomodulators: from cell to potential clinical benefit.
Thromb Haemost.
2003;
90
607-610
72
Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell R N.
Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins.
Circulation.
2003;
108
2113-2120
73
Sakai M, Kobori S, Matsumura T et al..
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Atherosclerosis.
1997;
133
51-59
74
Bellosta S, Via D, Canavesi M et al..
HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages.
Arterioscler Thromb Vasc Biol.
1998;
18
1671-1678
75
Bourcier T, Libby P.
HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells.
Arterioscler Thromb Vasc Biol.
2000;
20
556-562
76
Masamura K, Oida K, Kanehara H et al..
Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family.
Arterioscler Thromb Vasc Biol.
2003;
23
512-517
77
Egashira K, Hirooka Y, Kai H et al..
Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.
Circulation.
1994;
89
2519-2524
78
Treasure C B, Klein J L, Weintraub W S et al..
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
N Engl J Med.
1995;
332
481-487
79
Anderson T J, Meredith I T, Yeung A C, Frei B, Selwyn A P, Ganz P.
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
N Engl J Med.
1995;
332
488-493
80
Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T.
Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.
Circulation.
1997;
95
76-82
81
Wilson S H, Simari R D, Best P J et al..
Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering.
Arterioscler Thromb Vasc Biol.
2001;
21
122-128
82
Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G.
Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.
Am J Cardiol.
2001;
88
1306-1307
83
Tsunekawa T, Hayashi T, Kano H et al..
Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days.
Circulation.
2001;
104
376-379
84
Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G.
Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
Circ Res.
2003;
93
e98-103
85
Giroux L M, Davignon J, Naruszewicz M.
Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages.
Biochim Biophys Acta.
1993;
1165
335-338
86
Leonhardt W, Kurktschiev T, Meissner D et al..
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals.
Eur J Clin Pharmacol.
1997;
53
65-69
87
Aviram M, Fuhrman B.
LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants.
Mol Cell Biochem.
1998;
188
149-159
88
Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F.
A comparative study of the in vitro antioxidant activity of statins.
Int J Cardiol.
2003;
90
317-321
89
Shishehbor M H, Brennan M L, Aviles R J et al..
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
Circulation.
2003;
108
426-431
90
Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M.
Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Atherosclerosis.
2002;
164
179-185
91
Law M R, Wald N J, Rudnicka A R.
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
BMJ.
2003;
326
1423
92
Lesaffre E, Kocmanova D, Lemos P A, Disco C M, Serruys P W.
A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS.
Clin Ther.
2003;
25
2431-2447
93
Expert N CEP.
Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA.
2001;
285
2486-2497
94
Group HPSC .
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Lancet.
2002;
360
7-22
95
Kinlay S, Schwartz G G, Olsson A G et al..
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Circulation.
2004;
110
386-391
96
Shepherd J, Blauw G J, Murphy M B et al..
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Lancet.
2002;
360
1623-1630
97
O'Keefe Jr J H, Cordain L, Harris W H, Moe R M, Vogel R.
Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal.
J Am Coll Cardiol.
2004;
43
2142-2146
98
Velican C, Velican D.
The precursors of coronary atherosclerotic plaques in subjects up to 40 years old.
Atherosclerosis.
1980;
37
33-46
99
Aikawa M, Sivam P N, Kuro-o M et al..
Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis.
Circ Res.
1993;
73
1000-1012
100
Glueck C J, Kelley W, Gupta A, Fontaine R N, Wang P, Gartside P S.
Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I.
Metabolism.
1997;
46
625-633
100a
Nissen S E, Tuzcu E M, Schoenhagen P et al..
Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
N Engl J Med.
2005;
352
29-38
101
Nickenig G.
Should angiotensin II receptor blockers and statins be combined?.
Circulation.
2004;
110
1013-1020
102
Weiss D, Sorescu D, Taylor W R.
Angiotensin II and atherosclerosis.
Am J Cardiol.
2001;
87
25C-32C
103
Cannon C P.
Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial).
Am J Cardiol.
2002;
90
760-762
104
Bocan T M, Krause B R, Rosebury W S et al..
The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Arterioscler Thromb Vasc Biol.
2000;
20
70-79
105
Perrey S, Legendre C, Matsuura A et al..
Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.
Atherosclerosis.
2001;
155
359-370
106
Ziouzenkova O, Perrey S, Marx N, Bacqueville D, Plutzky J.
Peroxisome proliferator-activated receptors.
Curr Atheroscler Rep.
2002;
4
59-64
107
Farnier M, Salko T, Isaacsohn J L, Troendle A J, Dejager S, Gonasun L.
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
Am J Cardiol.
2003;
92
794-797
108
Ballantyne C M, Houri J, Notarbartolo A et al..
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Circulation.
2003;
107
2409-2415
109
Kastelein J.
What future for combination therapies?.
Int J Clin Pract Suppl.
2003;
134
45-50
110
Wald N J, Law M R.
A strategy to reduce cardiovascular disease by more than 80%.
BMJ.
2003;
327
1419
111
Jaffer F A, Weissleder R.
Seeing within: molecular imaging of the cardiovascular system.
Circ Res.
2004;
94
433-445
Masanori AikawaM.D. Ph.D.
Brigham and Women's Hospital, 77 Avenue Louis Pasteur
NRB 741, Boston, MA 02115